Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 18/20 | 0.58 |
| ▸ | TNF | P01375 | 1/20 | 0.34 |
| ▸ | SELP | P16109 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25413950 | 1.00 | TLR4 (0.58) | TLR4TNFSELP | |
| SCHEMBL25413433 | 0.95 | TLR4 (0.59) | TLR4TNFSELP | |
| SCHEMBL25413442 | 0.95 | TLR4 (0.59) | TLR4TNFSELP | |
| SCHEMBL26980076 | 0.95 | TLR4 (0.59) | TLR4SELP | |
| SCHEMBL25412006 | 0.95 | TLR4 (0.59) | TLR4SELP | |
| SCHEMBL25414669 | 0.93 | TLR4 (0.63) | TLR4SELP | |
| SCHEMBL25414674 | 0.88 | TLR4 (0.64) | TLR4SELP | |
| SCHEMBL25414680 | 0.88 | TLR4 (0.64) | TLR4SELP | |
| SCHEMBL25413780 | 0.87 | TLR4 (0.63) | TLR4SELP | |
| SCHEMBL25413774 | 0.87 | TLR4 (0.63) | TLR4SELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240002425-A1 | NOVEL AMINOALKYL GLUCOSAMINIDE 4-PHOSPHATE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-01-04 | — | — | US | disclosed |
| EP-4245763-A1 | NOVEL AMINOALKYL GLUCOSAMINIDE 4-PHOSPHATE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2023-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002425-A1 | NOVEL AMINOALKYL GLUCOSAMINIDE 4-PHOSPHATE DERIVATIVE | TLR4, TLR5, TLR9 | TLR4 1/4885TNF 2512/4885SELP 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.